Dynavax Technologies Corporation (DVAX)

Over the past six months, Dynavax's stock price has been influenced by several events, including a share price decline of 10.47% between October 2024 and October 2025. JMP Securities reissued a "Market Outperform" rating for DVAX with a $32.00 price target in August 2025, and Wall Street Zen upgraded Dynavax's stock from a "hold" to a "buy" rating. The company reported its Q2 2025 earnings on August 7, 2025, exceeding analyst expectations. Positive topline data was announced from Part 1 of its Phase 1/2 clinical trial for Z-1018, its shingles vaccine candidate, and an update was provided on its ongoing Phase 2 study for the rF1V-1018 vaccine, aimed at preventing pneumonic plague. In Q2 2025, the company repurchased shares worth $70.91 million, part of a $200 million share repurchase program initiated in November 2024. At the 2025 Annual Meeting, stockholders elected all four of the company's director nominees amidst a public dispute with Deep Track Capital.

Information regarding specific demand seasonality for Dynavax Technologies Corp.'s products and services was not found in the provided search results.

Dynavax Technologies Corp. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to protect against infectious diseases, operating within the Biotechnology industry. The company's core business revolves around the development and commercialization of novel vaccines, leveraging its proprietary adjuvant technology. Its major commercial product is HEPLISAV-B®, a hepatitis B vaccine approved in the U.S. and the European Union for adults aged 18 and older. Dynavax also produces CpG 1018 adjuvant, utilized in HEPLISAV-B® and multiple adjuvanted COVID-19 vaccines, and is actively advancing a pipeline of vaccine candidates, including those for shingles (Z-1018), Tdap, and plague (rF1V-1018).

Dynavax Technologies Corp. is headquartered in Emeryville, California, United States. The company's operations and market presence extend to the U.S. and Europe, and it has employees across North America, Europe, and Oceania.

In the past year, Dynavax's brand reputation has been influenced by positive clinical advancements and broader industry challenges. Positive results from its shingles vaccine candidate and the ongoing development of a pneumonic plague vaccine contribute positively to its reputation. Analyst upgrades and "Market Outperform" ratings also reflect a favorable view from the financial community. However, regulatory concerns regarding vaccine access and child immunization, as well as a public dispute with Deep Track Capital, could have impacted its reputation among investors.

Dynavax Technologies Corp. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional shareholders hold a substantial portion of the stock, with 95.34% institutional ownership reported. Major institutional owners include Deep Track Capital, LP, BlackRock, Inc., and Vanguard Group Inc. Bvf Partners L P is identified as the largest individual Dynavax Technologies shareholder, owning 21.01% of the company's shares. Other significant institutional holders include IJR - iShares Core S&P Small-Cap ETF, State Street Corp, and Chicago Capital, LLC.